{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T23:09:10Z","timestamp":1790636950658,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","atherosclerosis-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.atherosclerosis.2015.03.023","type":"journal-article","created":{"date-parts":[[2015,3,29]],"date-time":"2015-03-29T11:15:15Z","timestamp":1427627715000},"page":"639-646","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":158,"title":["Rivaroxaban, a novel oral anticoagulant, attenuates atherosclerotic plaque progression and destabilization in ApoE-deficient mice"],"prefix":"10.1016","volume":"242","author":[{"given":"Tomoya","family":"Hara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiju","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8261-1854","authenticated-orcid":false,"given":"Kimie","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasutomi","family":"Higashikuni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichiro","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachiko","family":"Nishimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shusuke","family":"Yagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotsugu","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Soeki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuzo","family":"Wakatsuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7835-7665","authenticated-orcid":false,"given":"Michio","family":"Shimabukuro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Sata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2015.03.023_bib1","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJM199901143400207","article-title":"Atherosclerosis\u2013an inflammatory disease","volume":"340","author":"Ross","year":"1999","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2015.03.023_bib2","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMra043430","article-title":"Inflammation, atherosclerosis, and coronary artery disease","volume":"352","author":"Hansson","year":"2005","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2015.03.023_bib3","doi-asserted-by":"crossref","first-page":"III20","DOI":"10.1161\/01.CIR.0000131514.71167.2e","article-title":"Inflammation in atherosclerosis and implications for therapy","volume":"109","author":"Paoletti","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2015.03.023_bib4","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1056\/NEJMra1011670","article-title":"The hemostatic system as a modulator of atherosclerosis","volume":"364","author":"Borissoff","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2015.03.023_bib5","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/00062752-200701000-00011","article-title":"Intertwining of thrombosis and inflammation in atherosclerosis","volume":"14","author":"Croce","year":"2007","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.atherosclerosis.2015.03.023_bib6","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1161\/01.ATV.0000070100.47907.26","article-title":"Extracellular mediators in atherosclerosis and thrombosis: lessons from thrombin receptor knockout mice","volume":"23","author":"Major","year":"2003","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2015.03.023_bib7","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1532\/IJH97.03165","article-title":"Progress in the understanding of protease-activated receptors","volume":"79","author":"Gabazza","year":"2004","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.atherosclerosis.2015.03.023_bib8","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.molmed.2008.08.001","article-title":"Factor Xa: at the crossroads between coagulation and signaling in physiology and disease","volume":"14","author":"Borensztajn","year":"2008","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.atherosclerosis.2015.03.023_bib9","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00281-011-0289-1","article-title":"Protease-activated receptor 2 signaling in inflammation","volume":"34","author":"Rothmeier","year":"2012","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.atherosclerosis.2015.03.023_bib10","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1093\/cvr\/cvt343","article-title":"Pleiotropic effects of factor Xa and thrombin: what to expect from novel anticoagulants","volume":"101","author":"Spronk","year":"2014","journal-title":"Cardiovasc Res."},{"key":"10.1016\/j.atherosclerosis.2015.03.023_bib11","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1038\/nm.2461","article-title":"Tissue factor-protease-activated receptor 2 signaling promotes diet-induced obesity and adipose inflammation","volume":"17","author":"Badeanlou","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.atherosclerosis.2015.03.023_bib12","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1161\/01.CIR.89.3.1262","article-title":"Specific factor Xa inhibition reduces restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits","volume":"89","author":"Ragosta","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2015.03.023_bib13","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1538-7836.2005.01166.x","article-title":"In\u00a0vitro and in\u00a0vivo studies of the novel antithrombotic agent BAY 59-7939\u2013an oral, direct factor Xa inhibitor","volume":"3","author":"Perzborn","year":"2005","journal-title":"J.\u00a0Thromb. Haemost."},{"key":"10.1016\/j.atherosclerosis.2015.03.023_bib14","doi-asserted-by":"crossref","first-page":"5900","DOI":"10.1021\/jm050101d","article-title":"Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor","volume":"48","author":"Roehrig","year":"2005","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.atherosclerosis.2015.03.023_bib15","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nrd3185","article-title":"The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor","volume":"10","author":"Perzborn","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.atherosclerosis.2015.03.023_bib16","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(09)60738-8","article-title":"Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial","volume":"374","author":"Mega","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2015.03.023_bib17","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2015.03.023_bib18","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.amjcard.2013.04.011","article-title":"Comparison of the efficacy and safety of two rivaroxaban doses in acute coronary syndrome (from ATLAS ACS 2-TIMI 51)","volume":"112","author":"Mega","year":"2013","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2015.03.023_bib19","first-page":"355","article-title":"Histologic, hematologic, and biochemical characteristics of apo E-deficient mice: effects of dietary cholesterol and phytosterols","volume":"79","author":"Moghadasian","year":"1999","journal-title":"Lab. Invest"},{"key":"10.1016\/j.atherosclerosis.2015.03.023_bib20","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1161\/01.ATV.14.1.133","article-title":"ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree","volume":"14","author":"Nakashima","year":"1994","journal-title":"Arterioscler. Thromb."},{"key":"10.1016\/j.atherosclerosis.2015.03.023_bib21","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1177\/019262339702500104","article-title":"Apolipoprotein E-deficient mouse model of human atherosclerosis","volume":"25","author":"O'Neill","year":"1997","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.atherosclerosis.2015.03.023_bib22","doi-asserted-by":"crossref","first-page":"E496","DOI":"10.1152\/ajpendo.00509.2007","article-title":"Generation and characterization of two novel mouse models exhibiting the phenotypes of the metabolic syndrome: Apob48-\/-Lepob\/ob mice devoid of ApoE or Ldlr","volume":"294","author":"Lloyd","year":"2008","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.atherosclerosis.2015.03.023_bib23","series-title":"Practical Statistics for Medical Research","first-page":"179","article-title":"Comparing groups \u2013 continuous data","author":"Altman","year":"1991"},{"key":"10.1016\/j.atherosclerosis.2015.03.023_bib24","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1080\/01621459.1955.10501294","article-title":"A\u00a0multiple comparison procedure for comparing several treatments with a control","volume":"50","author":"Dunnett","year":"1955","journal-title":"J.\u00a0Am. Stat. Assoc."},{"key":"10.1016\/j.atherosclerosis.2015.03.023_bib25","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.2146\/ajhp070624","article-title":"Rivaroxaban: an oral direct inhibitor of factor Xa","volume":"65","author":"Gulseth","year":"2008","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.atherosclerosis.2015.03.023_bib26","first-page":"1","article-title":"Effect of rivaroxaban on thrombin-induced pro-inflammatory gene expression in human umbilical vein endothelial cells","volume":"9","author":"Ellinghaus","year":"2011","journal-title":"J.\u00a0Thromb. Haemost."},{"key":"10.1016\/j.atherosclerosis.2015.03.023_bib27","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/med.20118","article-title":"Macrophages: an elusive yet emerging therapeutic target of atherosclerosis","volume":"28","author":"Tiwari","year":"2008","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.atherosclerosis.2015.03.023_bib28","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2015.03.023_bib29","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1160\/TH11-11-0787","article-title":"Role of new anticoagulants for the prevention of venous thromboembolism after major orthopaedic surgery and in hospitalised acutely ill medical patients","volume":"107","author":"Ageno","year":"2012","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.atherosclerosis.2015.03.023_bib30","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jacc.2013.05.024","article-title":"The ATLAS ACS 2-TIMI 51 trial and the burden of missing data: (Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome ACS 2-Thrombolysis in myocardial infarction 51)","volume":"62","author":"Krantz","year":"2013","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2015.03.023_bib31","doi-asserted-by":"crossref","first-page":"A56","DOI":"10.1093\/eurheartj\/sut013","article-title":"Perspectives: direct and specific inhibition of factor Xa: an emerging therapeutic strategy for atherothrombotic disease","volume":"16","author":"Santos-Gallego","year":"2014","journal-title":"Eur. Heart J. Suppl."},{"key":"10.1016\/j.atherosclerosis.2015.03.023_bib32","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0014-2999(99)00902-4","article-title":"Antithrombotic efficacy of RPR208566, a novel factor Xa inhibitor, in a rat model of carotid artery thrombosis","volume":"389","author":"Heran","year":"2000","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.atherosclerosis.2015.03.023_bib33","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/0014-2999(94)90506-1","article-title":"Effect of a novel thrombin active-site inhibitor on arterial and venous thrombosis","volume":"259","author":"Schumacher","year":"1994","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.atherosclerosis.2015.03.023_bib34","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1161\/ATVBAHA.107.139402","article-title":"Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases","volume":"27","author":"Turpie","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2015.03.023_bib35","doi-asserted-by":"crossref","first-page":"432080","DOI":"10.1155\/2011\/432080","article-title":"Evaluation of plaque stability of advanced atherosclerotic lesions in apo E-deficient mice after treatment with the oral factor Xa inhibitor rivaroxaban","volume":"2011","author":"Zhou","year":"2011","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.atherosclerosis.2015.03.023_bib36","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1161\/CIRCULATIONAHA.109.907121","article-title":"Early atherosclerosis exhibits an enhanced procoagulant state","volume":"122","author":"Borissoff","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2015.03.023_bib37","doi-asserted-by":"crossref","first-page":"12077","DOI":"10.1073\/pnas.0504526102","article-title":"Synergistic induction of tissue factor by coagulation factor Xa and TNF: evidence for involvement of negative regulatory signaling cascades","volume":"102","author":"Hezi-Yamit","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"10.1016\/j.atherosclerosis.2015.03.023_bib38","doi-asserted-by":"crossref","first-page":"14910","DOI":"10.1074\/jbc.271.25.14910","article-title":"The proteinase-activated receptor 2 is induced by inflammatory mediators in human endothelial cells. Comparison with the thrombin receptor","volume":"271","author":"Nystedt","year":"1996","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2015.03.023_bib39","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1182\/blood-2013-08-523936","article-title":"Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease","volume":"123","author":"Sparkenbaugh","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.atherosclerosis.2015.03.023_bib40","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1111\/j.1538-7836.2004.00968.x","article-title":"The physiology of vitamin K nutriture and vitamin K-dependent protein function in atherosclerosis","volume":"2","author":"Berkner","year":"2004","journal-title":"J.\u00a0Thromb. Haemost."},{"key":"10.1016\/j.atherosclerosis.2015.03.023_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0043229","article-title":"Vitamin K-antagonists accelerate atherosclerotic calcification and induce a vulnerable plaque phenotype","volume":"7","author":"Schurgers","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.atherosclerosis.2015.03.023_bib42","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1111\/j.1538-7836.2008.03064.x","article-title":"DU-176b, a potent and orally active factor Xa inhibitor: in\u00a0vitro and in\u00a0vivo pharmacological profiles","volume":"6","author":"Furugohri","year":"2008","journal-title":"J.\u00a0Thromb. Haemost."},{"key":"10.1016\/j.atherosclerosis.2015.03.023_bib43","doi-asserted-by":"crossref","first-page":"5339","DOI":"10.1021\/jm070245n","volume":"50","author":"Pinto","year":"2007","journal-title":"J.\u00a0Med. Chem."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915015001835?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915015001835?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T02:14:26Z","timestamp":1691547266000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915015001835"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S0021915015001835"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2015.03.023","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rivaroxaban, a novel oral anticoagulant, attenuates atherosclerotic plaque progression and destabilization in ApoE-deficient mice","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2015.03.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}